Improving statistical analysis of prospective clinical trials in stem cell transplantation. An inventory of new approaches in survival analysis

Aurelien Latouche

*University of Versailles, aurelien.latouche@uvsq.fr
This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commercially reproduced without the permission of the copyright holder.
http://biostats.bepress.com/cobra/art70
Copyright ©2010 by the author.
Improving statistical analysis of prospective clinical trials in stem cell transplantation. An inventory of new approaches in survival analysis

Aurelien Latouche

Abstract

The CLINT project is an European Union funded project, run as a specific support action, under the sixth framework programme. It is a 2 year project aimed at supporting the European Group for Blood and Marrow Transplantation (EBMT) to develop its infrastructure for the conduct of trans-European clinical trials in accordance with the EU Clinical Trials Directive, and to facilitate International prospective clinical trials in stem cell transplantation. The initial task is to create an inventory of the existing biostatistical literature on new approaches to survival analyses that are not currently widely utilised. The estimation of survival endpoints is introduced, with an emphasis on recent developments which complements standard analysis. The issues raised are new regression models that allow the estimation of time dependent effect for cause specific hazard, cumulative incidence and more generally mean response. New development in multi state model, with notably, recent regression models that assess the influence of covariates directly on transition probabilities are detailed. Some recent test for comparing cumulative incidence function across treatment arm are introduced. The estimation of centre effect in multi centric studies is also documented. Sample size calculation in the presence of competing risks are then presented. We close with the inventory of available packages and macro in R that implement the previous survival models.
Abstract

The CLINT 1 is an European union-funded project, run as a specific support action, under the Sixth Framework Programme. It is a 2 year project aimed at supporting the European Group for Blood and Marrow Transplantation (EBMT) to develop its infrastructure for the conduct of trans-European clinical trials in accordance with the European union clinical trials directive, and to facilitate international prospective clinical trials in stem cell transplantation. The initial task was to create an inventory of the existing biostatistical literature on new approaches to survival analyses that were not currently widely utilised.

The estimation of survival endpoints is introduced, with an emphasis on recent developments which complements standard analysis. The issues raised are new regression models that allow the estimation of time dependent effect for cause specific hazard, cumulative incidence and more generally mean response. New development in multi state model, with notably, recent regression models that assess the influence of covariates directly on transition probabilities are detailed. Some recent test for comparing cumulative incidence function across treatment arm are introduced. The estimation of centre effect in multicentric studies is also documented. Sample size calculation in the presence of competing risks are then presented. We close with the inventory of available packages and macro in R that implement the previous survival models.

Keywords: clinical trial; competing risks; multistate model; centre effect; sample size

1 Introduction

Patients who undergo a hematopoietic graft, can encounter several events post transplant: namely engraftment, graft–versus–host–disease, relapse, non-relapse death, progression. To assess the effect of a treatment on such outcome, some specific survival model are needed. The Cox proportional hazards dominates the survival analysis for years, notably because of the ease of the interpretation. The use of this model is perfectly detailed in the classic book of Therneau and Grambsch [1]. The topics covered are: residuals analysis to test the proportional hazards assumption, the functional form of the covariate or influence of individuals, time–dependent effect/coefficient (time–varying effects), correlated observations such as repeated measures and frailty or random effects. Other textbooks include Klein and Moeschberger [2] (with an emphasis on hematology case studies), Kalbfleish and

---

1Establishment of infrastructure to support international prospective clinical trials in stem cell transplantation (CLINT)
Prentice [3], Hosmer and Lemeshow [4] and the revised edition Hosmer et al. [5] as well as Collett [6], Kleinbaum and Klein [7].

The hematology field is a very inspiring when it comes to statistical developments especially in survival analysis. A first look at the literature confirms this interest notably through methodological notes or review that populate medical reviews [8, 9, 10, 11]. These notes and articles focus mostly on comparison of regression for hazard rates and cumulative incidence functions [12, 13]. In this inventory we will consider, alternative modelling strategies that complements the traditional proportional hazards model as well as estimations presented in the book of Therneau and Grambsch [1]. Recent books covering the topics are: Handbook of Statistics 23 [14], Dynamic Regression Models for Survival Data [15].

Before, investigating what were the advances since 2000 in survival analysis. It is of interest to list what are up to now the major tool at–hands. Major advances in survival analysis are the Survival R–package by T. Therneau [16], Multistate modelling, Tests for comparison of cumulative incidence functions [17], Regression model for the cumulative incidence and Fine–Gray model, Additive hazard model (Aalen, Scheike) [15]. All these points will be exemplified in the sequel.

In the main hematological reviews there are very comprehensive recommendation on the respective merits of up–to–date methods. This is mostly due to JP Klein (Medical College of Wisconsin) and colleagues that disseminate appropriate methodologies in the stem cell transplantation field [8, 9]. For example in a review paper Kim [11] introduced the pseudo–value estimation method for regressing the cumulative incidence functions. This method is new but is already made available (in principle) to applied statisticians. Another striking, example is the dissemination of the Fine–Gray model for the subdistribution of a competing risk. This is mostly due to the availability of a R–package. Indeed, the lack of statistical software that implements novel methodologies leads to underuse models. In that respect, in this inventory, we focused on model with ready–to–use software or routines.

In the first part, we recall standard notation and statistical models. Next we introduce prognostic factor analysis with the regression modelling and hypothesis tests. We close with a synthesis of statistical softwares and add–on package.

2 Statistical Models

In this section, we introduce the major statistical models when the interest is the analysis of time–to–event failure.

2.1 Survival model

The standard survival model focuses on a single endpoint. Recent developments are numerous, notably we identified, alternative methods (or tests) for the comparison of survival curves.

Usually, comparison of survival curves among randomization arms are performed at a fixed time–point. Klein et al. [18], investigated the performance of naive test (difference between the two survival curves).

Logan et al. [19] focused on crossing survival curves (that contradict the PH assumptions). A number of methods for comparing two survival curves after a prespecified time point. This situation may be of interest when the survival curves are expected to cross, so that we are only interested in late difference. Another, recent developments is the study of alternative endpoint, such as the Progression Free Survival (PFS) [20].

http://biostats.bepress.com/cobra/art70
2.2 Multistate models

Since the papers of Klein et al. [21], Keiding et al. [22] the multi–state approach, is becoming more popular but remain solely in hematopoietic stem cell transplantation (HSCT). The use of multistate in HSCT is not particularly new [21, 23]. One possible reason is that a multi-state model regression analysis typically involves the modelling of each transition intensity separately. Each probability of interest, namely the probability that a subject will be in a given state at some time, is a complex nonlinear function of the intensity regression coefficients. Thus, interpretation in terms of probability is quite complicated (even if depict the patient more closely) and the interpretation of hypothetical predictions from multi-state models in HSCT have to be avoided. An interesting example of the versatility of the multi-state model is the Current Leukemia Free Survival. In this example, the patient move between 9 states [24, 25, 26].

There exists an extensive literature on multi-state model. Main contributions include books by Andersen et al. [27] and Hougaard [28]. Recent reviews on this topic may be found in Hougaard [29], Andersen and Keiding [30]. An issue of the Journal Statistical Methods in Medical Research, entirely devoted to these models, was published in 2002. Despite its potentialities, multi-state modelling is not used by practitioners as frequently as other survival analysis techniques. Lack of knowledge of the available software as well as misunderstanding of what multi-state modellings advantages rely on (compared to the simple Cox model), are probably responsible for this lack of popularity.

The paper of Andersen et al. [31] entitled Competing risks as a multistate model, gave a fresh and unified view about multi–state model and competing risks. Recent development of Scheike and Zhang [32] that suggested a direct modelling of regression effects for transition probabilities should bring this framework up–front.

R–script of the tutorial from Putter et al. [33] can be found at http://www.msbi.nl/multistate. For a comprehensive review, we suggest the work of Meira–Machado and tdc.msm script [34]. More recently a R–package mvna provides plots and estimates of the cumulative hazards as a function of time for all the transitions specified by the user.

2.3 Competing risks model

For simplicity and tractability we will consider 2 competing events to introduce fundamental quantities.. In HSCT setting, this will usually be relapse and death in remission aka non relapse mortality.

The observed data typically consist in an observation time $\tilde{T}$ which is the minimum of a failure time $T$ and a censoring time $C$ and a status indicator $\varepsilon$. $\varepsilon = 0$ if the observation is censored ($C < T$). If $T > C$, then $\varepsilon$ denotes the observed cause of failure with $\varepsilon = 1$ for the event of interest and $\varepsilon = 2$ for the other competing event. Most common analyses focus on comparing the cause–specific hazard under the control and the experimental treatment [35], where the cause–specific hazard of failure from cause 1 in treatment arm E (resp C for control) is defined as:

$$\lambda_{1E}(t) = dF_{1E}(t)/S_{E}(t)$$

with $F_{1E}$ is the cumulative incidence function of failure from the cause of interest, i.e. $F_{1E}(t) = \Pr(T \leq t, \varepsilon = 1)$ and $S_{E}(t) = 1 - (F_{1E}(t) + F_{2E}(t))$ is the event free survival function. In such a case, comparisons of cause–specific hazards between groups are performed against proportional hazards alternatives, using a Cox model. The other strategy consists in comparing the corresponding event probabilities $F_{1E}(t)$ and $F_{1C}(t)$, either directly the Gray’s test [17] or using a Cox-like model for the associated hazard $\alpha_{1E}(t) = dF_{1E}(t)/(1 - F_{1E}(t))$, referred as the subdistribution hazard [13].

3
Figure 1: Competing risks model with cause-specific hazard for relapse $\lambda_1(t)$ and cause-specific hazard for death $\lambda_2(t)$.

The subdistribution hazard is directly related to the cumulative incidence function while the relation between cause–specific hazard and cumulative incidence involves the cause–specific hazard of the competing event. Another key remark is that these two models cannot hold simultaneously, i.e. proportional cause–specific hazards imply non–proportional subdistribution hazards.

It seems now established that these two models should be used simultaneously to fully depict the complex course of the patients. A detailed discussion of the relative merits of both approaches and their interpretation can be found in the paper of Beyersmann and Schumacher [36]. Tutorial on competing risks analysis are provided by Putter et al. [33] (with EBMT data) and in other field such time–to–seroconversion collaborative group such as CASCADE [37] provide guidelines for analysis of competing risks data.

To estimate the treatment benefit, it is recommended to adjust treatment comparison for potential confounders, based on regression models. For competing risks data, two main approaches have been used, either the Cox model [12] or Therneau and Grambsch [1, Chapter 8.4], or the recently proposed Fine and Gray model [13] and Martinussen and Scheike [15, Chapter 10]. Despite its rather recent origin, the Fine–Gray model has been quickly put to use in applications such as neutrophils recovery after bone marrow transplantation [38], infectious complications after blood stem-cell transplantation [39].

The models take subtly different approaches to competing risks data, and it is important to understand this for proper interpreting these respective results. Both the Cox and the Fine–Gray model analyze data from a competing risks setting as displayed in Figure 1. We observe a so-called failure time $T$ between start of remission and relapse/death, whatever comes first. One can think of time $T$ as the time spent in the remission state until moving into one of the competing risk states (relapse) or (death without prior relapse). Attached to these competing risks are cause-specific hazards $\lambda_1(t)$ and $\lambda_2(t)$; these can be thought of as ‘instantaneous forces’ that draw an individual towards the respective competing risks. More precisely, $\lambda_1(t)$ multiplied by a very, very small time interval is the probability of relapsing within this small time interval under the condition that the individual has still been relapse-free at the beginning of this time interval.

Hazards are, in fact, a very elusive concept [40], but analysis and interpretation is straightforward in usual survival analysis. A usual Cox model would look at the all-cause hazard $\lambda(t) = \lambda_1(t) + \lambda_2(t)$, which has a one-to-one correspondence to the distribution of the failure time $T$ through

$$P(T \leq t) = 1 - \exp \left( - \int_0^t \lambda(u) \, du \right),$$

i.e. the proportion of patients experiencing death or relapse (whatever comes first), as time progresses. Due to this one-to-one correspondence, a decreasing treatment effect found in a Cox model means a
decrease in this proportion, and an increasing effect entails an increase in this proportion.

However, things become surprisingly difficult with competing risks. We may still fit Cox models, but as is apparent from Figure 1 we will need to fit two Cox models, one for each cause-specific hazard, see, e.g., [1, p. 177]. The interpretation of these results then becomes involved, because the CIF for relapse, say, depends on both cause-specific hazards, and it does so in a rather complicated way [41]. In fact, we have for the CIF of relapse

\[ \text{CIF}_1(t) = P(T \leq t, \text{Relapse at} t) = \int_0^t \exp \left( - \int_0^u \lambda_1(v) + \lambda_2(v) \, dv \right) \cdot \lambda_1(u) \, du \]

These difficulties have led to the Fine–Gray model [13], with the aim of doing a Cox-type analysis for a quantity which reestablishes the one-to-one correspondence to the CIF of relapse.

This quantity has come to be known as the subdistribution hazard for relapse, and we write \( \lambda^{FG}(t) \) for it. The aim is to reestablish

\[ \text{CIF}_1(t) = P(T \leq t, \text{Relapse at} T) = 1 - \exp \left( - \int_0^t \lambda^{FG}(u) \, du \right) \]

for the CIF of relapse.

Finally, we should note that the Fine and Gray model for the subdistribution hazard \( \lambda^{FG}(t) \) and classical Cox models for the cause-specific hazards \( \lambda_1(t) \) of relapse and \( \lambda_2(t) \) of death are different models [42].

3 Regression Models

In this section we introduce recent regression models for the identifiable quantities namely, cause-specific hazard, cumulative incidence and conditional probability function. It should be pointed out that novel methodologies translate faster in medical journal. For example, the pseudo value approach introduced in 2003 is exemplified in a practical context in medical journal such as *Biology of Blood and Marrow Transplantation* [10] or [11].

3.1 Proportional hazards model

To relate the cause-specific hazard on the exposure covariate \( Z \), the Cox proportional hazards model is often used while a similar model was proposed for the subdistribution hazard [13]. The Cox model expresses the cause-specific hazard as a multiplicative function of the baseline instantaneous hazard, \( \lambda_k(t) = \lambda_{k0}(t) \exp(\beta Z) \), where \( \beta \) is the covariate effect. The Fine and Gray model focuses on the hazard associated with the CIF and similarly expresses as \( \alpha_k(t) = \alpha_{k0}(t) \exp(\gamma Z) \).

The Fine–Gray model, draw a lot of attention (from 2002) since its first use in HSCT. As a result several publications investigated the interpretation of the subdistribution hazard ratio [43]. The following references extend the Fine–Gray model or adapt standard methodologies to it [43, 44, 45, 46, 47, 36, 48]. Sun et al. [49] suggested a flexible additive multiplicative hazard model for modeling the subdistribution hazard.

In a recent paper Peng and Huang [50] propose a natural generalization of the Cox regression model, in which the regression coefficients have direct interpretations as temporal covariate effects on the survival function. Second-stage inferences with time-varying coefficients are developed accordingly. Simulations and a real example illustrate the practical utility of the proposed method.
3.2 Andersen–Klein model

A method based on pseudo-values has been proposed for direct regression modeling of the survival function \([51, 52, 53, 19]\). The pseudo value method is an estimating method. It enables the estimations of the following regression parameter, in a linear model for the CIF that was proposed by Fine \([54]\). The model for the CIF of type 1 is

\[ g(F_1(t; Z)) = h(t) - Z \beta. \]  

(1)

The parameter \(h(t)\) is the baseline failure probability, unspecified, invertible and strictly increasing in \(t\). This general transformation model includes the Fine–Gray model taking \(g(x) = \log\{-\log(1 - x)\}\).

The Andersen–Klein model is an alternative estimation techniques for the model 1. Recently, in a series of papers, a method based on pseudo-values has been proposed for direct regression modeling of the survival function, the restricted mean and cumulative incidence function with right censored data.

\[ g(F_1(t)) = F_{10}(t) + R(t)Z(t) \]  

(2)

Note that this model encompasses time-dependent covariates through \(Z(t)\) but requires that a grid or series of time points be specified. Usually 5 to 10 time points suffice to adequately model the CIF. The regression estimator of the parameter \(R(t)\) is based on pseudovalues from the cumulative incidence function. Interestingly, the model (2), once the pseudo-values have been computed, can be fit using standard generalized estimating equation software. The use of these routines to obtain regression estimates for a study of bone marrow transplant patients is detailed in Klein et al. \([53]\). The model 2 is implemented in the \textit{pseudo} R–package.

Another appealing regression strategy is the Direct Binomial Regression \([55]\) suggesting a new simple approach for estimation and assessment of covariate effects for the cumulative incidence curve in the competing risks model. They consider a semiparametric regression model where some effects may be time-varying and some may be constant over time. Their estimator can be implemented by standard software. Their simulation study shows that the estimator works well and has finite-sample properties comparable with the subdistribution approach. This methodology was exemplified to estimate the cumulative incidence of death in complete remission following a bone marrow transplantation. Interestingly, this regression model extends the Fine–Gray model, with time–dependent coefficients.

3.3 Time–dependent effects: The additive approach

A comprehensive description of additive model can be found in Martinussen and Scheike \([15]\). This class of model alternative is The Cox-Aalen additive-multiplicative intensity model that comprise a multiplicative part (Like a Cox model) and an additive part (like Aalen model). One interesting feature is that time-dependent effect and time-dependent covariate are easily handle indeed such properties violate the PH hazards assumptions.

Another important motivation for alternative modelling is pointed out in the recent work of Klein \([56]\) the proportional hazard transition in multistate model can lead to inconsistencies. The additive models for either the hazard rates or the cumulative incidence functions are more \textit{natural} and that these models properly partition the effect of a covariate on treatment failure into its component parts. These models are illustrated on data from a study of the efficacy of two preparative regimens for hematopoietic stem cell transplantation. Such findings must translate rapidly in HSCT.
Methods for fitting the Cox model with time-varying effects exist [57, 58, 59], but they all require some kind of smoothing thus depending on some smoothing parameter or sieve approximation. The obtained results may depend on the particular choice. The additive hazards regression model is an alternative (or supplement) to the Cox model. It was proposed by Aalen [60], and is very flexible non-parametric model. It results in plots that are informative regarding the effect of covariates on survival. The additive model of Aalen [60] specify the following relation between hazard and covariates:

$$\lambda_i(t) = \beta_0(t) + \beta_1(t)X_{i1}(t) + \ldots + \beta_p(t)X_{ip}(t)$$

An interesting submodel was suggested by McKeague and Sasieni [61]

$$\lambda_i(t) = \exp(\beta(t)^TZ_i(t) + \gamma^T Z_i(t))$$.

As pointed out by Klein [56], there is no guarantee that the estimated hazard is positive but this situation is very unlikely. The Martinussen–Scheike [62] model is a new additive-multiplicative hazard model which consists of two components. The first component contains additive covariate effects through an additive Aalen model while the second component contains multiplicative covariate effects through a Cox regression model. The Aalen model allows for time-varying covariate effects, while the Cox model allows only a common time-dependence through the baseline. This model is implemented in the \texttt{timereg R–package}.

### 3.4 Temporal process regression

This temporal process regression is a functional generalised linear model which specifies the mean of a response $Y(t)$ at time $t$ conditionally on a vector of possibly time-dependent covariates $Z(t)$, that is

$$E(Y(t)|Z(t)) = g^{-1}(\beta(t)^TZ(t)),$$

where the link function $g$ is monotone, differentiable and invertible. This is a very general model that encompass as particular case models such as logistic prevalence model. This model is implemented in the R–package \texttt{tpr}. A case study of this model can be found in the recent work of Allignol et al. [63] where this general regression framework was used to assess the effect of covariate on the conditional probability of a competing event [64].

### 4 Centre effect

A common question arising in multi-centre prospective clinical trials and in collaborative registry studies, is whether some heterogeneity in outcomes could be expected across centres, and, if such an heterogeneity exists, whether some statistical adjustment is required when estimating the prognostic effects of fixed covariates or not.

Recent developments with an emphasis in HSCT are [65, 66, 45, 67]. Centre-effects are usually investigated with shared frailty models, and this presumes that this effect is constantly present during the follow-up, even when the follow-up is very long. More realistic are models with time-varying frailties. Therefore, the constant centre-specific frailty model was extended to allow time dependence of the frailties [66]. Notably, the center effect was adapted to the Fine–Gray model [45] introducing a random-effects model for the subdistribution hazard. This work was exemplified on data provided by the EBMT.
5 2–Sample Tests

In this section we introduce recent test statistics that are of great interest in the field of HSCT. Notably because, these tests have higher power to detect crossing hazards. In this section the terminology hazard will refer to CSH or SH. The major tests used in survival analysis are the log–rank test for comparing the equality of cause–specific hazards and the the Gray test for the comparison of subdistribution hazards. Crossing survival curves may be a consequence of crossing hazards and it is well known that for this situation many standard tests, such as the log-rank or Wilcoxon tests, will fail to pick up differences in survival curves [18]. Freidlin and Korn [35] formally compared the performance of log–rank and Gray’s test. Small sample behaviour of variance estimator were investigated in Braun and Yuan [68]. Renyi type test was proposed as an alternative empowering users to detect differences between crossing hazards. It is a censored-data analogue of the Kolmogorov-Smirnov statistic and is based on the supremum of the absolute value of the entire path of the log-rank test statistic.

Bajorunaite and Klein [69] proposed a 2–sample tests for comparing cumulative incidence. The test statistic is based on the maximum difference between two cumulative incidence functions and a second test based on the integrated weighted difference between the cumulative incidence functions for the event of interest in two samples (based on Pepe [70]’s test).

6 Sample size calculation

We have seen that numerous derivation of regression models are proposed for the analysis of effect of covariates. An essential step when planning a trial is the calculation of the sample size or the number of patients to recruit to detect a relevant effect with sufficient power. In HSCT, patients enrolled in a clinical trial may experience exclusive failure causes, which defines a competing risk setting. For instance, in hematology patients receiving a bone marrow transplantation may experience two exclusive events such as relapse and non-relapse death. Planning a trial when competing endpoints are acknowledged to exist thus requires appropriate methodology. Notably, when some (primary) endpoints rely on cumulative incidence inference, this must be accounted for when calculating a required number of events.

For both proportional cause–specific hazard and subdistribution hazards, sample size where derived in the presence of competing events [43, 71]. Both are based on Schoenfeld [72]’s formula and rely on similar key parameters, namely the hazard ratio that quantifies the treatment effect to be detected and the proportion of patients who are expected to fail from the cause of interest.

A sample size formula for the supremum log-rank test has also been recently presented in the classical survival framework [73]. It may be useful to anticipate possible departures from proportional hazards by using a test statistic less sensitive to this proportionality assumption. This is the case of Renyi-type tests also know as supremum log-rank tests in the classical survival framework [1416]. Recent work on sample size has shown that this test is nearly as efficient as the log-rank test when hazards are proportional, and can accommodate broader range of alternatives where the log-rank has no power to distinguish between groups. Additionally, Renyi-type test statistics have already been extended to the comparison of CIFs in the unpublished Ph.D. thesis of R. Bajorunaite. The Renyi-type tests are based on supremum integrated weighted difference of CIFs. We will refer to this test as the adapted Renyi-type test. More recently, Latouche and Porcher [47] suggested the use of supremum log–rank test and supremum Gray test.
7 Survival Analysis in R

A mandatory aspect for disseminating new statistical models is the availability of implementation. For example, the survival package enables standard analysis for Cox model and Kaplan–Meier estimations [16].

To facilitate dissemination of R–package, we produced a Task View that enable user to easily install the whole packages related to survival analysis. To automatically install these views, the ctv package needs to be installed, e.g., via

```
> install.packages("ctv")
> library("ctv")
```

and then the views can be installed via install.views or update.views install.views("Survival") or update.views("Survival")

The Survival View is located at http://cran.r-project.org/web/views/Survival.html. This was done thanks to the collaboration of Arthur Allignol (Freiburg).

8 Conclusion

We have attempted to review recent developments in survival analysis and competing risks, with an emphasis on HSCT. The relevance of the use of such recent models are now established in the HSCT. In that respect the journal Lifetime Data Analysis has published a dedicated issue on Statistical analysis of HSCT Data [74, 75]. A question raised by this inventory, is to know whether or not recent developments that bring new insights will reach applied statisticians/clinicians. One solution would be to give statistical courses or educational session each year on a regular basis. The CLINT portal could be the core of this training/teaching infrastructure http://clint.ebmt.org.

Acknowledgments

The author would like to thank JP Klein for his comments on the early version of this work.

References


http://biostats.bepress.com/cobra/art70